SELLAS Life Sciences
28 hedge funds and large institutions have $4.42M invested in SELLAS Life Sciences in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 3 closing their positions.
871% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $141K
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
8% more funds holding
Funds holding: 26 → 28 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.86% less ownership
Funds ownership: 14.51% → 10.65% (-3.9%)
33% less capital invested
Capital invested by funds: $6.64M → $4.42M (-$2.22M)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$193K |
| 2 |
Two Sigma Investments
New York
|
+$88.9K |
| 3 |
Millennium Management
New York
|
+$68.4K |
| 4 |
Charles Schwab
San Francisco,
California
|
+$44.8K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$36.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$1.71M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$566K |
| 3 |
Morgan Stanley
New York
|
-$105K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$54K |
| 5 |
Renaissance Technologies
New York
|
-$31.6K |
SLS Hedge Fund Activity: Q3 2022 in Review
28 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in SELLAS Life Sciences (SLS) for Q3 2022, worth a combined $4.42M — down 33% from $6.64M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SLS positions and 3 closed out — a net gain of 2 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $193K. The largest seller was Empery Asset Management, cutting an estimated $1.71M.
- 28 institutional investors held SELLAS Life Sciences (SLS) as of Q3 2022, up from 26 in Q2 2022.
- Funds reported $4.42M of SELLAS Life Sciences stock for Q3 2022, down 33% quarter-over-quarter.
- 5 funds opened new SELLAS Life Sciences positions in Q3 2022 and 3 closed out, a net change of +2 holders.
- The largest SELLAS Life Sciences buyer in Q3 2022 was Citadel Advisors, an estimated $193K added.
- The largest SELLAS Life Sciences seller in Q3 2022 was Empery Asset Management, an estimated $1.71M sold.
Based on aggregated 13F filings for Q3 2022.